TY - JOUR
T1 - Evaluation of neointimal morphology of lesions with or without in-stent restenosis
T2 - An optical coherence tomography study
AU - Lee, Sung Joo
AU - Kim, Byeong Keuk
AU - Kim, Jung Sun
AU - Ko, Young Guk
AU - Choi, Donghoon
AU - Jang, Yangsoo
AU - Hong, Myeong Ki
PY - 2011/10
Y1 - 2011/10
N2 - Background: Characterization of neointimal tissue is essential to understand the pathophysiology of in-stent restenosis (ISR) after drug-eluting stent (DES) implantation. Using optical coherence tomography (OCT), we compared the morphologic characteristics of in-stent neointimal tissue from 33 ISR lesions with those of 192 non-ISR lesions after DES implantation. Hypothesis: We hypothesized that the morphologic characteristics of in-stent neointimal tissue from ISR lesions were different from those of non-ISR lesions after DES implantation. Methods: The DES were coated with sirolimus (n=52), paclitaxel (n=57), zotarolimus (n=84), or everolimus (n=32). In-stent restenosis was defined as ≥50% diameter stenosis at the follow-up angiogram. Lesions with ≥10% neointimal burden ([neointima area × 100]/[stent area]), as determined by OCT, were included in this study. A follow-up OCT (mean follow-up duration, 12.0 ± 10.5 mo) was performed in 209 patients with 225 lesions (ISR lesions, n=33; non-ISR lesions, n=192). Qualitative OCT was used to assess tissue structure, backscatter, visible microvessels, and presence of intraluminal material. Results: The following characteristics were more common in ISR lesions than in non-ISR lesions: heterogeneous or layered tissues (78.8% vs 22.9%, P<0.001), low backscatter (60.6% vs 20.8%, P<0.001), and microvessels (48.5% vs 5.7%, P<0.001). The independent predictors for heterogeneous or layered neointimal tissues were increased neointima burden (odds ratio [OR]: 1.218, 95% confidence interval [CI]: 1.096-1.354, P<0.001), lumen area (OR: 4.672, 95% CI: 1.371-15.914, P = 0.014), and hypertension (OR: 0.415, 95% CI: 0.186-0.926, P = 0.032). Conclusions: This follow-up OCT study demonstrated that morphologic characteristics of neointimal tissues of ISR lesions differ from those of non-ISR lesions.
AB - Background: Characterization of neointimal tissue is essential to understand the pathophysiology of in-stent restenosis (ISR) after drug-eluting stent (DES) implantation. Using optical coherence tomography (OCT), we compared the morphologic characteristics of in-stent neointimal tissue from 33 ISR lesions with those of 192 non-ISR lesions after DES implantation. Hypothesis: We hypothesized that the morphologic characteristics of in-stent neointimal tissue from ISR lesions were different from those of non-ISR lesions after DES implantation. Methods: The DES were coated with sirolimus (n=52), paclitaxel (n=57), zotarolimus (n=84), or everolimus (n=32). In-stent restenosis was defined as ≥50% diameter stenosis at the follow-up angiogram. Lesions with ≥10% neointimal burden ([neointima area × 100]/[stent area]), as determined by OCT, were included in this study. A follow-up OCT (mean follow-up duration, 12.0 ± 10.5 mo) was performed in 209 patients with 225 lesions (ISR lesions, n=33; non-ISR lesions, n=192). Qualitative OCT was used to assess tissue structure, backscatter, visible microvessels, and presence of intraluminal material. Results: The following characteristics were more common in ISR lesions than in non-ISR lesions: heterogeneous or layered tissues (78.8% vs 22.9%, P<0.001), low backscatter (60.6% vs 20.8%, P<0.001), and microvessels (48.5% vs 5.7%, P<0.001). The independent predictors for heterogeneous or layered neointimal tissues were increased neointima burden (odds ratio [OR]: 1.218, 95% confidence interval [CI]: 1.096-1.354, P<0.001), lumen area (OR: 4.672, 95% CI: 1.371-15.914, P = 0.014), and hypertension (OR: 0.415, 95% CI: 0.186-0.926, P = 0.032). Conclusions: This follow-up OCT study demonstrated that morphologic characteristics of neointimal tissues of ISR lesions differ from those of non-ISR lesions.
UR - http://www.scopus.com/inward/record.url?scp=80054122183&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80054122183&partnerID=8YFLogxK
U2 - 10.1002/clc.20960
DO - 10.1002/clc.20960
M3 - Article
C2 - 21928365
AN - SCOPUS:80054122183
VL - 34
SP - 633
EP - 639
JO - Clinical Cardiology
JF - Clinical Cardiology
SN - 0160-9289
IS - 10
ER -